u/StockyJ122

2 theses · first seen Aug 23, 2026

Window	Theses	Resolved	Wins	Win rate	Avg return	Median return
1d	1	1	0	0%	-1.2%	-1.2%
3d	2	2	1	50%	+3.8%	+3.8%
1w	2	2	2	100%	+6.4%	+6.4%
1m	0	0	0	—	—	—
3m	0	0	0	—	—	—
6m	0	0	0	—	—	—
1y	0	0	0	—	—	—

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$BMEAr/pennystocksGeneral Discussionbullish

u/StockyJ122 · 44d ago1 prior · awaiting results

$BMEA ($1.8) -- Another $7 price target by Citizens

Citi reiterates a $7 price target on BMEA citing two upcoming catalysts: the BMF-650 data next month and COVALENT-211 trial results in Q1 2027. The latter could be a major catalyst if it demonstrates a 0.5%+ A1c reduction in this difficult-to-treat population, validating the menin inhibitor's potential and suggesting significant upside from current levels.

At post $1.73Now $1.32-23.7% since postedas of Oct 7, 4:30 PM ET

1d-1.2%

3d0.0%

1w+4.0%

1m-13.9%

3m—

6m—

1y—

original post →

$BMEAr/pennystocksBullishbullish

u/StockyJ122 · 45d ago1 prior · awaiting results

Citi predicts 410% rally for BMEA (currently under $1.50)

Citi analyst rates BMEA a Buy with a $7 price target (410% upside from $1.37), driven by anticipated positive Phase 1 weight-loss data for BMF-650, an oral GLP-1 candidate with promising early efficacy comparable to or better than competitors.

At post $1.59Now $1.32-17.0% since postedas of Oct 7, 4:30 PM ET

1d—

3d+7.5%

1w+8.8%

1m+6.9%

3m—

6m—

1y—

original post →

End of results.